Literature DB >> 35907989

Assessment of the PARITY Sub-Analysis "Neoadjuvant Chemotherapy and Endoprosthetic Reconstruction for Lower Extremity Sarcomas: Does Timing Impact Complication Rates?"

Lauren Zeitlinger1, R Lor Randall2.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35907989     DOI： 10.1245/s10434-022-12307-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   4.339


× No keyword cloud information.
  4 in total

1.  Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication rates.

Authors:  Thomas L Sutton; Nathalie Johnson; Alexander Schlitt; Stuart K Gardiner; Jennifer R Garreau
Journal:  Am J Surg       Date:  2020-03-10       Impact factor: 2.565

2.  Risk of amputation following limb salvage surgery with endoprosthetic replacement, in a consecutive series of 1261 patients.

Authors:  L M Jeys; R J Grimer; S R Carter; R M Tillman
Journal:  Int Orthop       Date:  2003-02-08       Impact factor: 3.075

3.  Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma.

Authors:  Hamayun Imran; Felicity Enders; Mark Krailo; Franklin Sim; Scott Okuno; Douglas Hawkins; Joseph Neglia; R Lor Randall; Richard Womer; Leo Mascarenhas; Carola A S Arndt
Journal:  J Bone Joint Surg Am       Date:  2009-03-01       Impact factor: 5.284

4.  Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial.

Authors:  Michelle Ghert; Patricia Schneider; Gordon Guyatt; Lehana Thabane; Roberto Vélez; Timothy O'Shea; R Lor Randall; Robert Turcotte; David Wilson; Jay S Wunder; André Mathias Baptista; Edward Y Cheng; Yee-Cheen Doung; Peter C Ferguson; Victoria Giglio; James Hayden; Diane Heels-Ansdell; Shah Alam Khan; Venkatesan Sampath Kumar; Paula McKay; Benjamin Miller; Michiel van de Sande; Juan P Zumárraga; Mohit Bhandari
Journal:  JAMA Oncol       Date:  2022-03-01       Impact factor: 33.006
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.